Hans‐Peter Hartung

65.8k total citations · 11 hit papers
730 papers, 43.0k citations indexed

About

Hans‐Peter Hartung is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology. According to data from OpenAlex, Hans‐Peter Hartung has authored 730 papers receiving a total of 43.0k indexed citations (citations by other indexed papers that have themselves been cited), including 319 papers in Pathology and Forensic Medicine, 256 papers in Neurology and 154 papers in Immunology. Recurrent topics in Hans‐Peter Hartung's work include Multiple Sclerosis Research Studies (307 papers), Peripheral Neuropathies and Disorders (208 papers) and Hereditary Neurological Disorders (78 papers). Hans‐Peter Hartung is often cited by papers focused on Multiple Sclerosis Research Studies (307 papers), Peripheral Neuropathies and Disorders (208 papers) and Hereditary Neurological Disorders (78 papers). Hans‐Peter Hartung collaborates with scholars based in Germany, United States and Austria. Hans‐Peter Hartung's co-authors include Bernd C. Kieseier, Gilles Edan, Chris H. Polman, Fred Lublin, Jerry S. Wolinsky, Ludwig Kappos, Magnhild Sandberg‐Wollheim, Alan J. Thompson, Stephen C. Reingold and Henry F. McFarland and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Hans‐Peter Hartung

715 papers receiving 41.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

2001 5.4k citations Hans‐Peter Hartung et al. profile →
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

2005 4.0k citations Hans‐Peter Hartung, Ludwig Kappos et al. profile →
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 1.6k citations Hans‐Peter Hartung, Xavier Montalbán et al. New England Journal of Medicine profile →
Guillain–Barré Syndrome

2012 749 citations Hans‐Peter Hartung et al. New England Journal of Medicine profile →
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds.

1999 723 citations Franz Fazekas, Hans‐Peter Hartung et al. profile →
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome

1998 676 citations Hans‐Peter Hartung et al. profile →
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

2002 669 citations Hans‐Peter Hartung et al. profile →
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

2010 630 citations Hans‐Peter Hartung et al. profile →
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

1994 623 citations Hans‐Peter Hartung et al. profile →
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

1996 562 citations Hans‐Peter Hartung et al. Neurology profile →
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

2016 335 citations Bruce Cree, Hans‐Peter Hartung et al. profile →

Peers

Countries citing papers authored by Hans‐Peter Hartung

Since Specialization

Citations

This map shows the geographic impact of Hans‐Peter Hartung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Hartung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Hartung more than expected).

Fields of papers citing papers by Hans‐Peter Hartung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Peter Hartung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Hartung. The network helps show where Hans‐Peter Hartung may publish in the future.

Co-authorship network of co-authors of Hans‐Peter Hartung

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Peter Hartung. A scholar is included among the top collaborators of Hans‐Peter Hartung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Peter Hartung. Hans‐Peter Hartung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic relevance of the C‐X‐C motif chemokine ligand 13 and interleukin‐8 in predicting the transition from clinically isolated syndrome to multiple sclerosis 2024 ·European Journal of Neuroscience ·(unknown), Jan Mareš, Ondřej Sobek, (unknown), (unknown), Milan Raška, Hans‐Peter Hartung	2
2	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis 2021 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), Michael Dietrich, (unknown), (unknown), (unknown), (unknown), (unknown), Klaudia Lepka, Jonas Graf, Norbert Goebels, Hans‐Peter Hartung, Orhan Aktaş, Sven G. Meuth, Philipp Albrecht, Iris‐Katharina Penner	16
3	Targeting B Cells to Modify MS, NMOSD, and MOGAD 2021 ·Neurology Neuroimmunology & Neuroinflammation ·Jonas Graf, Jan Mareš, Michael Barnett, Orhan Aktaş, Philipp Albrecht, Scott S. Zamvil, Hans‐Peter Hartung	41
4	Relapse-independent multiple sclerosis progression under natalizumab 2021 ·Brain Communications ·Jonas Graf, Verena I. Leussink, (unknown), Klaudia Lepka, Ingrid Meinl, Tania Kümpfel, Sven G. Meuth, Hans‐Peter Hartung, Joachim Havla, Orhan Aktaş, Philipp Albrecht	26
5	NK cell markers predict the efficacy of IV immunoglobulins in CIDP 2020 ·Neurology Neuroimmunology & Neuroinflammation ·Anne K. Mausberg, (unknown), Gerd Meyer zu Hörste, (unknown), Michael Fleischer, Fabian Szepanowski, Christoph Kleinschnitz, Hans‐Peter Hartung, Bernd C. Kieseier, Mark Stettner	12
6	Ocrelizumab shorter infusion 2020 ·Neurology Neuroimmunology & Neuroinflammation ·Hans‐Peter Hartung	18
7	Comparison of different optomotor response readouts for visual testing in experimental autoimmune encephalomyelitis-optic neuritis 2020 ·Journal of Neuroinflammation ·Christina Hecker, Michael Dietrich, Andrea Issberner, Hans‐Peter Hartung, Philipp Albrecht	11
8	Serum neurofilament light chain 2020 ·Neurology Neuroimmunology & Neuroinflammation ·Orhan Aktaş, (unknown), André Huss, (unknown), (unknown), (unknown), (unknown), Klaudia Lepka, Norbert Goebels, Makbule Şenel, Jonas Graf, Christian Enzinger, Daniela Pinter, Gerald Antoch, Bernd Turowski, Hans‐Peter Hartung, Philipp Albrecht, Markus Otto, Hayrettin Tumani, Iris‐Katharina Penner	33
9	Occipital repetitive transcranial magnetic stimulation does not affect multifocal visual evoked potentials 2020 ·BMC Neuroscience ·(unknown), (unknown), Ann‐Kristin Müller, Marius Ringelstein, Orhan Aktaş, Alfons Schnitzler, Hans‐Peter Hartung, Stefan Jun Groiss, Philipp Albrecht	1
10	Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats 2019 ·Journal of Visualized Experiments ·Michael Dietrich, Christina Hecker, Alexander Hilla, Andrés Cruz-Herranz, Hans‐Peter Hartung, Dietmar Fischer, Ari Green, A Philipp	1
11	Meningitis gone viral: description of the echovirus wave 2013 in Germany 2019 ·BMC Infectious Diseases ·Jonas Graf, Christian J. Hartmann, Helmar C. Lehmann, Carolin Otto, Ortwin Adams, Michael Karenfort, Christian Schneider, Klemens Ruprecht, Hans Martin Bosse, Sabine Diedrich, Sindy Böttcher, Alfons Schnitzler, Hans‐Peter Hartung, Orhan Aktaş, Philipp Albrecht	7
12	Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy 2019 ·Neurology ·Philipp Albrecht, (unknown), John‐Ih Lee, Orhan Aktaş, Hans Bigalke, Hans‐Peter Hartung, Harald Hefter	3
13	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study 2018 ·Multiple Sclerosis Journal ·Jeffrey A. Cohen, Giancarlo Comi, Douglas L. Arnold, Amit Bar‐Or, Krzysztof Selmaj, Lawrence Steinman, Eva Havrdová, Bruce Cree, Xavier Montalbán, Hans‐Peter Hartung, Vivian Huang, Paul Frohna, Brett E. Skolnick, Ludwig Kappos, (unknown)	39
14	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis 2018 ·Journal of Neurochemistry ·Jens Ingwersen, Lorenzo De Santi, Britta Wingerath, Jonas Graf, Barbara Koop, Reiner Schneider, Christina Hecker, Friederike Schröter, (unknown), (unknown), Michael Dietrich, Philipp Albrecht, Hans‐Peter Hartung, Pasquale Annunziata, Orhan Aktaş, Tim Prozorovski	28
15	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension 2017 ·Journal of Neurology ·Philipp Albrecht, (unknown), Marius Ringelstein, Ann‐Kristin Müller, David Finis, Rainer Guthoff, (unknown), Wolf A. Lagrèze, Orhan Aktaş, Hans‐Peter Hartung, Friedemann Paul, Alexander U. Brandt, Axel Methner	50
16	More on PML in Patients Treated with Dimethyl Fumarate. 2016 ·New England Journal of Medicine ·Kristian Reich, Hans‐Peter Hartung, Mark Lebwohl	6
17	Review of teriflunomide and its potential in the treatment of multiple sclerosis 2009 ·SHILAP Revista de lepidopterología ·Clemens Warnke, (unknown), Hans‐Peter Hartung, (unknown), et al.	11
18	Estimation of magnetization transfer rates from PACE experiments with pulsed RF saturation 2000 ·Journal of Magnetic Resonance Imaging ·Stefan Ropele, Rudolf Stollberger, Hans‐Peter Hartung, Franz Fazekas	14
19	Estimation of magnetization transfer rates from PACE experiments with pulsed RF saturation 2000 ·Journal of Magnetic Resonance Imaging ·Stefan Ropele, Rudolf Stollberger, Hans‐Peter Hartung, Franz Fazekas	1
20	Microglia and macrophages are major sources of locally produced transforming growth factor-?1 after transient middle cerebral artery occlusion in rats 1998 ·Glia ·Elin Lehrmann, Reinhard Kiefer, Thomas Christensen, Klaus V. Toyka, Jens Zimmer, Nils Henrik Diemer, Hans‐Peter Hartung, Bente Finsen	161

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact